Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer, Monsanto India...

    Bayer, Monsanto India mega-merger worth USD 63 billion gets clearance from NCLT

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-14T09:15:29+05:30  |  Updated On 14 Sept 2019 9:15 AM IST
    Bayer, Monsanto India mega-merger worth USD 63 billion gets clearance from NCLT

    Bayer CropScience took shareholders' approval for the merger during the first quarter of 2019-20 and was waiting for the final approval of the NCLT to make the global merger effective in India.


    New Delhi: The National Company Law Tribunal (NCLT) on Friday approved the merger of biotech company Monsanto India Ltd with Bayer CropScience.


    In June 2018, German chemical and pharma major Bayer AG had announced the completion of the USD 63 billion mega-deal to acquire US-based biotech major Monsanto to create the world's biggest agro-chemical and seed company.


    Bayer had in May received approval from the fair trade regulator Competition Commission of India (CCI), paving way for the completion of the global merger.


    Bayer CropScience took shareholders' approval for the merger during the first quarter of 2019-20 and was waiting for the final approval of the NCLT to make the global merger effective in India.


    "...the Mumbai Bench of the NCLT has on September 13, 2019, conveyed its approval for the Scheme of Amalgamation of Monsanto India Ltd with Bayer CropScience Ltd and their respective shareholders, under sections 230 to 232 of the Companies Act, 2013," Bayer CropScience said in a regulatory filing.


    Read Also: Bayer disagrees with German Government decision to ban Glyphosate from end of 2023


    The Scheme will become effective after the company files the certified copy of the NCLT order along with the amalgamation scheme with the Registrar of Companies.


    Bayer Group is present in India since 1896 and has two divisions, which are crop science and pharmaceutical. It has one listed entity in India, Bayer CropScience Ltd.


    Read Also: Judge to reevaluate $80 million award in Monsanto cancer case

    Bayerbayer acquisitionbayer monsanto mergerCCICompetition Commission of IndiaMonsantoNational Company Law TribunalNCLTnclt approvalpharmapharma companypharma newspharma news india
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok